Although all four cancers have a substantial body of evidence and meta‐analyses, the focus of studies varies: lung cancer research emphasizes predicting response to immunotherapy, BC studies focus on triple‐negative and HER2‐positive subtypes, CRC research primarily addresses recurrence prediction after surgery, and PCa studies mainly concentrate on its role in CRPC. Here, ERBB2 is linked to breast cancer.